Managing Partner, GGV Capital Singapore
Armed with a degree in mathematics, biological sciences and a passion for solving the unsolvable, Piers Ingram eschewed convention when he left a high-flying commercial pharma career in 2015 and invested everything he had into the creation of Hummingbird Bioscience, a Singapore-based biotech company.
Today his company is competing alongside biopharma giants in the pursuit of delivering effective drug candidates against disease targets that conventional drug discovery methods have been unable to achieve.
In just five years, the company has successfully produced novel drug candidates against two of the most challenging oncology targets, as well as a rich pipeline of new candidates to address serious, hard-to-treat conditions, from cancer to autoimmune and infectious diseases.
Ingram says Hummingbird’s platforms have the potential to upend conventional drug discovery – often a hit-and-miss process – and transform the industry. In the past 12 months, Hummingbird has attracted partners such as Amgen and Cancer Research UK.
“COVID-19 has spurred the need for not only new innovations, but also the need for more efficient ways to bring these innovations to the fore,” Ingram tells Business Insider. “It is changing the way drug R&D is being done, and I believe that what we have created at Hummingbird will bring even more momentum to a faster, more efficient approach to drug discovery and will be able to make an impact across a broad spectrum of diseases.”